(HealthDay News) — The use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers is associated with lower risk of colorectal cancer risk that develops within 3 years after index colonoscopy, according to a study published online in Hypertension.

Ka Shing Cheung, MBBS, from the University of Hong Kong, and colleagues examined the association between use of ACE inhibitors and angiotensin receptor blockers and colorectal cancer risk after a negative baseline colonoscopy among patients aged ≥40 years who underwent colonoscopy between 2005 and 2013. Data were included for 187,897 eligible patients, of whom 16.4% were ACE inhibitor/angiotensin receptor blocker users.

The researchers found that between 6 and 36 months after index colonoscopy, 854 patients (0.45%) developed colorectal cancer. Reduced risk of colorectal cancer that developed less than 3 years after index colposcopy (adjusted hazard ratio, 0.78; 95% confidence interval, 0.64 to 0.96) but not more than 3 years (adjusted hazard ratio, 1.18; 95% confidence interval, 0.88 to 1.57) was seen in association with drug use. The investigators observed a 5% reduction in adjusted hazard ratio risk with every single year increase in drug use.

“Apart from side effects and contraindications, compelling indication is another factor to be considered in the choice of a particular antihypertensive medication,” the authors write. “Our study provided additional insights into the potential chemopreventive effects of ACE inhibitors/angiotensin receptor blockers against colorectal cancer development, apart from their known cardiovascular and renal benefits.”


Continue Reading

Two authors disclosed financial ties to the pharmaceutical industry.

Reference

Cheung KS, Chan EW, Seto WK, Wong ICK, Leungull WK. ACE (Angiotensin-Converting Enzyme) Inhibitors/Angiotensin Receptor Blockers Are Associated With Lower Colorectal Cancer Risk: A Territory-Wide Study With Propensity Score Analysis. Hypertension.